Science Explorer Back to mapMap
Discussion
Company · Jerusalem · Israel

Immunovative Therapies (Israel)

immunovative.comROR OpenAlex
Research works
5
▼ 100% vs 2018-21
Citations
53
11.0 per fractional work
Top-10% rate
4.3%
all institutions 10.0%
Open access
36%
world 40%
International
59%
world 18%
Immunovative Therapies (Israel)

Not ranked overall: Immunovative Therapies (Israel) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Immunovative Therapies (Israel) work in?

In all years, 67% of research at Immunovative Therapies (Israel) is in Life Sciences, 33% in Health Sciences. Its largest fields are Immunology and Microbiology (52%), Medicine (33%), Biochemistry, Genetics and Molecular Biology (15%). It does 1.7× the world's share of Life Sciences.

Life Sciences: 3 fractional works · 66.7% of its workImmunology and Microbiology: 2 fractional works · 52.1% of its workBiochemistry, Genetics and Molecular Biology: 1 fractional works · 14.6% of its workHealth Sciences: 2 fractional works · 33.3% of its workMedicine: 2 fractional works · 33.3% of its workALL ITS WORKImmunovativeTherapies…5fractional works, all years
Life Sciences67%Health Sciences33%

Each ring splits the one inside it: the four domains of science, their fields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 2 domains and 3 fields, with their numbers
    1. Immunology and Microbiology252.1%
    2. Biochemistry, Genetics and Molecular Biology114.6%
    1. Medicine233.3%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Who are the top researchers at Immunovative Therapies (Israel)?

Ranked on the quality score, Michael Har-Noy lead among researchers whose main affiliation is Immunovative Therapies (Israel).

  1. 1 Michael Har-Noy Israel · #2,788,052 worldwide 415 citations · 25 works
All ranked researchers at Immunovative Therapies (Israel)

What are the most cited papers from Immunovative Therapies (Israel)?

The most cited paper from Immunovative Therapies (Israel) is "Th-1 Lymphocytes Induce Dendritic Cell Tumor Killing Activity by an IFN-γ–Dependent Mechanism" (Collin J. LaCasse, Nona Janikashvili, Claire B. Larmonier et al., 2011), with 52 citations. Next come "Allogeneic effector/memory Th-1 cells impair FoxP3+ regulatory T lymphocytes and synergize with chaperone-rich cell lysate vaccine to treat leukemia" (27) and "Allo-priming as a universal anti-viral vaccine: protecting elderly from current COVID-19 and any future unknown viral outbreak" (22).

Most cited papers
#PaperReleasedCitations
1 Th-1 Lymphocytes Induce Dendritic Cell Tumor Killing Activity by an IFN-γ–Dependent Mechanism Collin J. LaCasse, Nona Janikashvili, Claire B. Larmonier et al. · The Journal of Immunology Open access 10 Nov 2011 52
2 Allogeneic effector/memory Th-1 cells impair FoxP3+ regulatory T lymphocytes and synergize with chaperone-rich cell lysate vaccine to treat leukemia Nona Janikashvili, Collin J. LaCasse, Claire B. Larmonier et al. · Blood Open access 2 Dec 2010 27
3 Allo-priming as a universal anti-viral vaccine: protecting elderly from current COVID-19 and any future unknown viral outbreak Michael Har-Noy, Reuven Or · Journal of Translational Medicine Open access 12 May 2020 22
4 Allogeneic CD3/CD28 cross-linked Th1 memory cells provide potent adjuvant effects for active immunotherapy of leukemia/lymphoma Michael Har-Noy, Michael Zeira, Lola Weiss et al. · Leukemia Research 2 Oct 2008 21
5 Prolonged remission of advanced bronchoalveolar adenocarcinoma in a dog treated with autologous, tumour-derived chaperone-rich cell lysate (CRCL) vaccine Laura M. Epple, Lynne Bemis, Ryan Patrick Cavanaugh et al. · International Journal of Hyperthermia Open access 20 Jun 2013 18
All 11 most cited papers, with filters and sorting

Which research topics does Immunovative Therapies (Israel) publish most on?

By volume in 2022-now: Immune cells in cancer, Respiratory viral infections research, interferon and immune responses and Cancer Cells and Metastasis.

Immune cells in cancer0Immune cells in cancer: 0 fractional worksRespiratory viral infect…0Respiratory viral infections research: 0 fractional worksinterferon and immune re…0interferon and immune responses: 0 fractional worksCancer Cells and Metastasis: 0 fractional worksImmunotherapy and Immune Responses: 0 fractional worksIntraperitoneal and Appe…0Intraperitoneal and Appendiceal Malignancies: 0 fractional works
ImmunologyEpidemiologyOncologySurgery

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Immune cells in cancer Immunology 0 works
  2. 2 Respiratory viral infections research Epidemiology 0 works
  3. 3 interferon and immune responses Immunology 0 works
  4. 4 Cancer Cells and Metastasis Oncology 0 works
  5. 5 Immunotherapy and Immune Responses Immunology 0 works
  6. 6 Intraperitoneal and Appendiceal Malignancies Surgery 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available36.1%not open63.9%

World: 40% of research is openly available.

with international co-authors58.7%domestic only41.3%

World: 18% is written across borders.

How has Immunovative Therapies (Israel)'s research output changed?

Output in 2022-2025 was 100% lower than in 2018-2021.

still counting2010201520202025
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Jerusalem

All research institutions in Jerusalem

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Immunovative Therapies (Israel). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.